EICHORCondition: Lung Cancer, Non-Small Cell · Sponsor: GlaxoSmithKline
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is a multicenter, randomized, double-blind, placebo-controlled study of niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance therapy in participants with advanced or metastatic non-small cell lung cancer (NSCLC) who have achieved stable disease (SD), partial response (PR), or complete response (CR) following completion of standard of care first-line (SoC 1L) platinum-based induction chemotherapy with pembrolizumab. The primary hypotheses are: participants with confirmed diagnosis of NSCLC could benefit from niraparib plus pembrolizumab versus placebo plus pembrolizumab with respect to Progression-free survival (PFS) and Overall survival (OS).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Fullerton, California, United States | — |
| GSK Investigational Site | Los Angeles, California, United States | — |
| GSK Investigational Site | Lone Tree, Colorado, United States | — |
| GSK Investigational Site | Norwich, Connecticut, United States | — |
| GSK Investigational Site | Tallahassee, Florida, United States | — |
| GSK Investigational Site | Atlanta, Georgia, United States | — |
| GSK Investigational Site | Newnan, Georgia, United States | — |
| GSK Investigational Site | Niles, Illinois, United States | — |
| GSK Investigational Site | Iowa City, Iowa, United States | — |
| GSK Investigational Site | Worcester, Massachusetts, United States | — |
| GSK Investigational Site | Mineola, New York, United States | — |
| GSK Investigational Site | New York, New York, United States | — |
+ 176 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04475939